Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when the EQ-5D-5L quality of life value set will be adopted in NICE technology appraisals.
Answered by Preet Kaur Gill
The National Institute for Health and Care Excellence (NICE) is planning to adopt the EQ-5D-5L value set and has recently consulted on proposed changes to its guidance development manuals. NICE is now considering the responses to the consultation and expects to implement changes to its methods in the coming months.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE on the introduction of EURneffy for use in the emergency treatment of serious allergies.
Answered by Preet Kaur Gill
Following the approval of an adrenaline nasal spray by the Medicines and Healthcare products Regulatory Agency (MHRA) in July 2025, the Government is considering whether any amendments to Schedule 17 of the Human Medicines Regulations 2012 are appropriate. Any changes to access arrangements would represent an amendment to the current regulatory framework and would require consideration of patient safety and appropriate clinical use. Should changes be proposed, a public consultation would be undertaken.
The National Institute of Health and Care Excellence (NICE) has been notified of the considerations being made by the Department in this area. NICE is not currently considering producing guidance on EURneffy. NICE will continue to monitor new evidence on this topic, in line with its usual processes. NICE has met with the National Institute for Health and Care Research which has agreed to explore whether research on this topic would be feasible and, if so, what research programme it might be suited to.
There are no restrictions on accessing information on how to use adrenaline devices, whether by a medical professional or member of the public. Guidance from the MHRA on their website and on YouTube includes information on the correct use of adrenaline auto-injectors and what to do in an emergency, with further information available at the following two links:
https://www.youtube.com/watch?v=4vNR5N1-iBw
The manufacturers of adrenaline devices also provide a range of training materials freely available to the public, including training devices without medication, guides on instructions for use, and video demonstrations.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what Barnett consequentials arise for Northern Ireland as a result of the £10 million per year funding announced to cover travel costs for children and young people with cancer in England.
Answered by Ashley Dalton
The Department knows that the cost of travel is an important issue for many young cancer patients and their families across the United Kingdom.
Through the National Cancer Plan, the Government is committing up to £10 million a year to a new fund open to all children and young people in England with cancer and their families regardless of income, to support them with the cost of travelling to and from Principal Treatment Centres. This commitment sits alongside wider action to transform cancer care for children and young people.
Health is predominately devolved. Devolved administrations receive funding through the Barnett Formula, and it is ultimately for them to allocate, prioritise, and manage their budgets. However, the Department does work closely with our counterparts in the devolved governments to share expertise and identify new opportunities to improve health and social care delivery across the UK.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with the Northern Ireland Department of Health and the Northern Ireland Executive to ensure that families of children and young people with cancer in Northern Ireland can benefit from support comparable to the travel cost scheme announced for England.
Answered by Ashley Dalton
The Department knows that the cost of travel is an important issue for many young cancer patients and their families across the United Kingdom.
Through the National Cancer Plan, the Government is committing up to £10 million a year to a new fund open to all children and young people in England with cancer and their families regardless of income, to support them with the cost of travelling to and from Principal Treatment Centres. This commitment sits alongside wider action to transform cancer care for children and young people.
Health is predominately devolved. Devolved administrations receive funding through the Barnett Formula, and it is ultimately for them to allocate, prioritise, and manage their budgets. However, the Department does work closely with our counterparts in the devolved governments to share expertise and identify new opportunities to improve health and social care delivery across the UK.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of Northern Ireland being the only part of the UK without routine access to abiraterone for men with non-metastatic prostate cancer on patient outcomes across the UK.
Answered by Zubir Ahmed
There are no current plans to hold discussions with the Northern Irish Department of Health or the Health and Social Care Board on abiraterone access in Northern Ireland. Decisions on the availability of medicines in Northern Ireland are a matter for the Northern Ireland Executive.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of Northern Ireland being the only part of the UK unable to offer abiraterone routinely to eligible prostate cancer patients.
Answered by Zubir Ahmed
There are no current plans to hold discussions with the Northern Irish Department of Health or the Health and Social Care Board on abiraterone access in Northern Ireland. Decisions on the availability of medicines in Northern Ireland are a matter for the Northern Ireland Executive.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has had discussions with the Northern Ireland (a) Department of Health and (b) Health and Social Care Board on levels of accessibility to abiraterone for non-metastatic prostate cancer across the UK.
Answered by Zubir Ahmed
There are no current plans to hold discussions with the Northern Irish Department of Health or the Health and Social Care Board on abiraterone access in Northern Ireland. Decisions on the availability of medicines in Northern Ireland are a matter for the Northern Ireland Executive.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with his counterpart in the Northern Ireland executive on the potential introduction of a national screening programme for prostate cancer.
Answered by Ashley Dalton
The UK National Screening Committee (UK NSC) advises ministers and the National Health Service in the four nations of the United Kingdom about all aspects of screening. The implementation of any UK NSC screening recommendation is a devolved matter.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent engagement he has had with the blood cancer community on the significance of implementing a proxy measure for early diagnosis in blood cancer.
Answered by Ashley Dalton
The Department continues to support the National Health Service to diagnose and treat cancer as early and fast as possible. There have been improvements in the prognosis of blood cancer patients, with patients now living twice as long. However, we recognise that because of the damaged NHS this Government inherited, patients with cancers with non-specific symptoms such as blood cancer, are waiting too long for diagnosis and subsequent treatment.
There are no current plans to introduce a specific proxy staging measure or a corresponding national target to support the earlier diagnosis of blood cancers. However, the Department will continue to engage with blood cancer charities and key stakeholders to determine how to support the best outcomes for blood cancer patients.
At this time no current assessment has been made on the potential merits of a proxy measure for early diagnosis in unstageable blood cancers. However, we remain committed to making improvements across different cancer types and reducing disparities in cancer survival. Early cancer diagnosis is also a specific priority within the NHS’s wider Core20Plus5 approach to reducing healthcare inequalities. The NHS currently track early diagnosis in stageable blood cancers by combining the percentage of diagnoses within stage 1 or 2, as it would for any other stageable cancer.
Furthermore, to tackle late, emergency setting diagnoses of blood cancers, the NHS is implementing non-specific symptom (NSS) pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. There are currently 115 NSS services operating in England with blood cancers being one of the most common cancer types diagnosed through these pathways.
The National Disease Registration Service (NDRS), through the National Cancer Registration and Analysis Services, collects information on how many people in England have cancer. Blood cancer is included as a distinct category, labelled haematological neoplasms. The NDRS website also shows the number of people treated for different tumour types by treatment type, as well as survival rates, mortality rates, and data on urgent suspected cancer referrals. Further information is available at the following link:
https://digital.nhs.uk/ndrs/data/data-outputs/cancer-data-hub
The National Cancer Plan will include further details on improving outcomes for cancer patients in England, as well as speeding up diagnosis and treatment. It will ensure patients, including those with blood cancer, have timely access to the latest treatments and technology.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will commit to engaging with the blood cancer community to agree on an appropriate measure for early diagnosis in blood cancer.
Answered by Ashley Dalton
The Department continues to support the National Health Service to diagnose and treat cancer as early and fast as possible. There have been improvements in the prognosis of blood cancer patients, with patients now living twice as long. However, we recognise that because of the damaged NHS this Government inherited, patients with cancers with non-specific symptoms such as blood cancer, are waiting too long for diagnosis and subsequent treatment.
There are no current plans to introduce a specific proxy staging measure or a corresponding national target to support the earlier diagnosis of blood cancers. However, the Department will continue to engage with blood cancer charities and key stakeholders to determine how to support the best outcomes for blood cancer patients.
At this time no current assessment has been made on the potential merits of a proxy measure for early diagnosis in unstageable blood cancers. However, we remain committed to making improvements across different cancer types and reducing disparities in cancer survival. Early cancer diagnosis is also a specific priority within the NHS’s wider Core20Plus5 approach to reducing healthcare inequalities. The NHS currently track early diagnosis in stageable blood cancers by combining the percentage of diagnoses within stage 1 or 2, as it would for any other stageable cancer.
Furthermore, to tackle late, emergency setting diagnoses of blood cancers, the NHS is implementing non-specific symptom (NSS) pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. There are currently 115 NSS services operating in England with blood cancers being one of the most common cancer types diagnosed through these pathways.
The National Disease Registration Service (NDRS), through the National Cancer Registration and Analysis Services, collects information on how many people in England have cancer. Blood cancer is included as a distinct category, labelled haematological neoplasms. The NDRS website also shows the number of people treated for different tumour types by treatment type, as well as survival rates, mortality rates, and data on urgent suspected cancer referrals. Further information is available at the following link:
https://digital.nhs.uk/ndrs/data/data-outputs/cancer-data-hub
The National Cancer Plan will include further details on improving outcomes for cancer patients in England, as well as speeding up diagnosis and treatment. It will ensure patients, including those with blood cancer, have timely access to the latest treatments and technology.